Egg Medical Inc. secured a $13 million investment from TVM Capital Life Science to solve the Humpty-Dumpty problem that plagues interventional cardiology – the scattering of radiation during X-ray guided procedures. The company’s Eggnest XR product contains the radiation using a carbon fiber platform with integrated radiation shielding that replaces the patient mattress on the X-ray table.

By using engineered retinal pigment epithelial cells to deliver IL-2 into the tumor microenvironment, investigators at Rice University eradicated ovarian and colorectal tumors in mouse models, and elicited T-cell responses after implantation in primates.

Amgen Inc.’s pioneering lung cancer drug, Lumykras (sotorasib), is set to become available to NHS patients in England, after cost-effectiveness body NICE recommended financing from the Cancer Drugs Fund (CDF) in final draft guidance.